Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
40 participants
INTERVENTIONAL
2025-06-25
2026-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MOWOOT Device Treatment for Adults With Chronic Constipation
NCT04666155
Efficacy of Interferential Therapy in Chronic Constipation (CON-COUR)
NCT02381665
Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation
NCT02676388
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
NCT03060512
Contribution of Percutaneous Endoscopic Caecostomie in the Management of Severe Constipation Refractory to Medical Treatment
NCT02566746
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Experimental ICE Group: Participants will receive one ICE treatment session lasting 20 minutes daily, at the same hour, for 12 weeks.
Control TAI Group: Participants will follow the usual TAI standard-of-care treatment for 12 weeks.
Participants will be given the option to choose between the ICE treatment and the TAI treatment after both options are explained to them. Healthcare professionals will recommend the most suitable treatment based on individual patient needs, but the final decision will rest with the patients.
The primary objective is to evaluate the change in satisfaction with daily quality of life related to bowel management, measured by a Likert scale (Bothersome scale). Secondary objectives include assessing the efficacy of the ICE treatment on chronic constipation, both qualitatively and quantitatively, and evaluating the economic impact from the hospital's perspective.
Secondary outcomes will be measured through various patient-reported and health professional-reported metrics, including changes in quality of life (PAC-QOL), constipation symptoms (PAC-SYM), constipation severity (CCCS), time spent in bowel management and evacuation, use of other treatments, number of consultations and hospital admissions, productivity, acceptability and ease of use of the ICE treatment, reported problems, compliance, adherence, and persistence in treatment. Health professional outcomes will include time spent per visit, total time spent until independent use of MOWOOT, ease of patient management, and patient treatment preferences.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental ICE Group
Each patient will receive 1 ICE treatment of 20 minutes at least once per day, every day at the same hour, during the intervention period of 12 weeks.
ICE Treatment
Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
Control TAI Group
Each patient will follow the usual TAI standard-of-care treatment for the intervention period of 12 weeks.
TAI Standard-of-Care Treatment
Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ICE Treatment
Each patient in the Experimental ICE Group will receive one Intermittent Colonic Exoperistalsis (ICE) treatment session lasting 20 minutes. These sessions will be conducted at least once per day, every day at the same hour, for a total duration of 12 weeks. The ICE treatment involves using the MOWOOT medical device designed to alleviate chronic constipation by stimulating colonic peristalsis.
TAI Standard-of-Care Treatment
Each patient in the Control TAI Group will follow the usual Trans-Anal Irrigation (TAI) standard-of-care treatment. This involves the regular use of TAI procedures as prescribed by healthcare professionals for the intervention period of 12 weeks. The TAI treatment is a well-established method for managing chronic constipation by mechanically clearing the bowel.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Attending their pre-scheduled on-site visit to the site (The Sir Alan Parks Physiology \& Pelvic Floor Biofeedback Unit \| Central Middlesex Hospital) due to constipation (Symptoms meeting the American College of Gastroenterology definition of chronic constipation: unsatisfactory defaecation characterized by infrequent stool, difficult stool passage or both for at least previous 3 months.
3. Bothered by their constipation
4. Failed biofeedback (in absence of outlet problems)
5. In waiting list to use TAI
6. Able to undertake the treatment with the MOWOOT device or TAI themselves, or with a carer willing to do it
7. Able to understand the study requirements
8. Able to understand written and spoken English (due to questionnaire validity)
9. Able and willing to provide written informed consent to participate
Exclusion Criteria
* Irritable Bowel Syndrome with Diarrhoea (IBS-D) or alternating constipation and diarrhoea (IBSmix): (not due to laxative use)
* Inflammatory Bowel Disease (IBD)
* Significant outlet problem
* Trapping rectocele
* Intra anal rectal intussusception
* External rectal prolapse
* Abdominal perimeter ≤65cm or ≥130cm
* Unable to independently use the MOWOOT technology, unless a carer is available daily to assist
Other medical conditions, medications and contraindications:
* Pregnancy or attempt to become pregnant in the next 6 months.
* Previous large bowel resection
* Active anorexia or bulimia
* Active abdominal cancer
* Large inguinal or umbilical hernia
* Recent abdominal scars, abdominal wounds or skin disorders that may make abdominal massage uncomfortable
* Any condition that contraindicates abdominal massage.
* Significant abdominal pain
* Participation in another parallel interventional clinical trial or less than 2 months from participation in a previous interventional clinical trial
* Planned surgery\* if it might be within trial dates (\* minor surgery not affecting adherence to treatment is allowed)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
usMIMA S.L.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gregory Thomas, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit | Central Middlesex Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Sir Alan Parks Physiology & Pelvic Floor Biofeedback Unit., Central Hospital, Department of Physiology, St Mark's Hospital, The National Bowel Hospital
London, London, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MOW-08-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.